Psychosocial and Clinical Predictors of Retention in Outpatient Alcoholism Treatment

Filho, João Maria Corrêa; Baltieri, Danilo Antônio

doi:10.1016/j.rbp.2012.03.003

Cited by 14 publications

(11 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Seventy (58%) of the 120 enrolled subjects completed the entire 24 week study which is within the expected range of retention (30 to 60%) for similar studies examining pharmacotherapy in alcohol dependent populations (Correa Filho et al, 2012; Oncken et al, 2001; Prisciandaro et al, 2011); 37 (53%) of the 70 completers were randomized to the BF arm and 33 (47%) were randomized to the PL arm (Table 2). The completion rate was 55% for the PL group and 63% for the BF group and these rates were not significantly different.…”

Section: Resultsmentioning

confidence: 72%

Double-blind, randomized placebo-controlled clinical trial of benfotiamine for severe alcohol dependence

Manzardo

Poje

et al. 2013

Drug and Alcohol Dependence

View full text Add to dashboard Cite

Background Alcohol dependence is associated with severe nutritional and vitamin deficiency. Vitamin B1 (thiamine) deficiency erodes neurological pathways that may influence the ability to drink in moderation. The present study examines tolerability of supplementation using the high-potency thiamine analogue, benfotiamine (BF), and BF’s effects on alcohol consumption in severely affected, self-identified, alcohol dependent subjects. Methods A randomized, double-blind, placebo-controlled trial was conducted on 120 non-treatment seeking, actively drinking, alcohol dependent men and women volunteers (mean age=47 years) from the Kansas City area who met DSM-IV-TR criteria current alcohol dependence. Subjects were randomized to receive 600 mg benfotiamine or placebo (PL) once daily by mouth for 24 weeks with 6 follow-up assessments scheduled at 4 week intervals. Side effects and daily alcohol consumption were recorded. Results Seventy (58%) subjects completed 24 weeks of study (N=21 women; N=49 men) with overall completion rates of 55% (N=33) for PL and 63% (N=37) for BF groups. No significant adverse events were noted and alcohol consumption decreased significantly for both treatment groups. Alcohol consumption decreased from baseline levels for 9 of 10 BF treated women after 1 month of treatment compared with 2 of 11 on PL. Reductions in total alcohol consumption over 6 months were significantly greater for BF treated women (BF: N=10, −611±380 Std Dev; PL: N=11, −159±562 Std Dev, p-value=0.02). Conclusions BF supplementation of actively drinking alcohol dependent men and women was well-tolerated and may discourage alcohol consumption among women. The results do support expanded studies of BF treatment in alcoholism.

show abstract

Section: Resultsmentioning

confidence: 72%

Double-blind, randomized placebo-controlled clinical trial of benfotiamine for severe alcohol dependence

Manzardo

Poje

et al. 2013

Drug and Alcohol Dependence

View full text Add to dashboard Cite

show abstract

“…Demographic characteristics have predicted dropout in some studies (e.g., younger age: Vuoristo-Myllys, Lahti, Alho, & Julkunen, 2013; male gender: Schilling and Sachs, 1993), whereas other studies have failed to identify significant demographic predictors (e.g., age: Ray, Hutchison, & Bryan, 2006; gender: Elbreder, de Souza e Silva, Pillon, & Laranjeira, 2011; Vuoristo-Myllys, Lahti, Alho, & Julkunen, 2013). Similarly, comorbid depression has been identified as a predictor of AD treatment dropout in some studies (e.g., Filho & Baltieri, 2012) and found unrelated to dropout in other studies (e.g., Kavanagh et al, 2006). Perhaps most illustrative of all, some studies have found that baseline drinking severity is associated with higher dropout (e.g., Graff et al, 2009), other studies have found it to predict lower dropout (e.g., Ray, Hutchinson, & Bryan, 2006), and still others have found it to be unrelated to dropout from AD treatment (e.g., Filho & Baltieri, 2012).…”

mentioning

confidence: 83%

“…Similarly, comorbid depression has been identified as a predictor of AD treatment dropout in some studies (e.g., Filho & Baltieri, 2012) and found unrelated to dropout in other studies (e.g., Kavanagh et al, 2006). Perhaps most illustrative of all, some studies have found that baseline drinking severity is associated with higher dropout (e.g., Graff et al, 2009), other studies have found it to predict lower dropout (e.g., Ray, Hutchinson, & Bryan, 2006), and still others have found it to be unrelated to dropout from AD treatment (e.g., Filho & Baltieri, 2012). …”

mentioning

confidence: 83%

Predictors of dropout in concurrent treatment of posttraumatic stress disorder and alcohol dependence: Rate of improvement matters

Zandberg

Rosenfield

Alpert

et al. 2016

Behaviour Research and Therapy

View full text Add to dashboard Cite

Objective The present study examined predictors and moderators of dropout among 165 adults meeting DSM-IV criteria for posttraumatic stress disorder (PTSD) and alcohol dependence (AD). Participants were randomized to 24 weeks of naltrexone (NAL), NAL and prolonged exposure (PE), pill placebo, or pill placebo and PE. All participants received supportive AD counseling (the BRENDA manualized model). Method Logistic regression using the Fournier approach was conducted to investigate baseline predictors of dropout across the entire study sample. Rates of PTSD and AD symptom improvement were included to evaluate the impact of symptom change on dropout. Results Trauma type and rates of PTSD and AD improvement significantly predicted dropout, accounting for 76% of the variance in dropout. Accidents and “other” trauma were associated with the highest dropout, and physical assault was associated with the lowest dropout. For participants with low baseline PTSD severity, faster PTSD improvement predicted higher dropout. For those with high baseline severity, both very fast and very slow rates of PTSD improvement were associated with higher dropout. Faster rates of drinking improvement predicted higher dropout among participants who received PE. Conclusions The current study highlights the influence of symptom trajectory on dropout risk. Clinicians may improve retention in PTSD-AD treatments by monitoring symptom change at regular intervals, and eliciting patient feedback on these changes.

show abstract

“…Histórico de tratamentos anteriores (13) 8. Dificuldade de comparecer em decorrência do trabalho (46) TOTAL 32…”

Section: Dimensão Tratamentounclassified

Dimensões Que Interferem Na Adesão À Medicação Nos Transtornos Relacionados Às Substâncias: Revisão Integrativa

Capistrano

Maftum²,

Alcantara

et al. 2019

Cogitare Enferm.

View full text Add to dashboard Cite

Objetivo: Analisar a produção científica acerca das dimensões que interferem na adesão à terapêutica medicamentosa de pessoas com transtornos mentais relacionados ao uso de substância, no período de 2006 a abril de 2017.Método: Revisão Integrativa da Literatura a partir de três bancos de dados, LILACS, CINAHL e PUBMED, realizada em abril de 2017.Resultados: Foram analisados 43 estudos que atendiam aos critérios de elegibilidade. A análise dos estudos possibilitou identificar fatores que impactam positiva ou negativamente a adesão à terapêutica medicamentosa, agrupados de acordo com as cinco dimensões determinantes para a adesão proposta pela Organização Mundial da Saúde, sendo elas: socioeconômica, equipe/sistema de saúde, doença, tratamento, e indivíduo/paciente.Conclusão: Embora a terapêutica medicamentosa seja imprescindível no gerenciamento da pessoa com transtorno relacionado a substâncias, muitas vezes representa um desafio devido às diferentes dimensões interativas que influenciam diretamente no processo de adesão.

show abstract

Psychosocial and Clinical Predictors of Retention in Outpatient Alcoholism Treatment

Cited by 14 publications

References 38 publications

Double-blind, randomized placebo-controlled clinical trial of benfotiamine for severe alcohol dependence

Double-blind, randomized placebo-controlled clinical trial of benfotiamine for severe alcohol dependence

Predictors of dropout in concurrent treatment of posttraumatic stress disorder and alcohol dependence: Rate of improvement matters

Dimensões Que Interferem Na Adesão À Medicação Nos Transtornos Relacionados Às Substâncias: Revisão Integrativa

Contact Info

Product

Resources

About